Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 3/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | BRD4 | O60885 | 1/20 | 0.31 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2288363 | 0.86 | DGAT1 (0.35) | DGAT1NPC1MAPTBRD4CREBBP | |
| SCHEMBL29825101 | 0.86 | DGAT1 (0.35) | DGAT1NPC1MAPTBRD4CREBBP | |
| SCHEMBL2290099 | 0.85 | EGFR (0.34) | DGAT1NPC1MAPTBRD4CREBBP | |
| SCHEMBL22620183 | 0.82 | DGAT1 (0.40) | DGAT1NPC1MAPTBRD4CREBBP | |
| SCHEMBL2287470 | 0.81 | DGAT1 (0.31) | DGAT1MAPT | |
| SCHEMBL566964 | 0.79 | KDM4E (0.34) | DGAT1NPC1MAPT | |
| SCHEMBL25285605 | 0.78 | MAPT (0.30) | MAPT | |
| SCHEMBL14697439 | 0.78 | PDE4B (0.35) | DGAT1MAPTBRD4CREBBP | |
| SCHEMBL30478940 | 0.78 | MAPT (0.30) | MAPT | |
| SCHEMBL10099303 | 0.77 | JAK2 (0.32) | MAPTBRD4CREBBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120034250-A1 | CONDENSED PYRROLOPYRIDINE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2012-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120034250-A1 | CONDENSED PYRROLOPYRIDINE DERIVATIVE | JAK2, JAK1, JAK3 | DGAT1 4419/4885NPC1 3590/4885MAPT 3074/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.